What the FDA decided on Orzeyful for Narcolepsy type 1
The FDA approved Orzeyful (oveporexton) for narcolepsy type 1.
Approved August 5, 2026 for adults with narcolepsy type 1 (narcolepsy with cataplexy). The FDA called it the first medicine to work by directly targeting the loss of orexin signaling that causes the disease. It is a tablet taken twice daily. It can be sold only after the DEA completes controlled substance scheduling, and Takeda listed expected availability by November 2026.
Who the Orzeyful decision matters to
Narcolepsy type 1 is a chronic neurologic disorder caused by loss of hypocretin-producing neurons, resulting in severe daytime somnolence and cataplexy. HLA-DQB1*0602 association and brain imaging support the autoimmune hypothesis.
Medications enhance wakefulness; behavioral approaches optimize quality of life.
Prevalence: 1 in 2,000 to 3,000 people; often undiagnosed. See our full Narcolepsy Type 1 page for current treatments, recruiting trials, and community resources.
How Orzeyful works
Orzeyful: oral orexin receptor 2 (OX2R) agonist that switches on the receptor normally activated by orexin, the wake-promoting brain chemical lost in narcolepsy type 1. Our full Orzeyful profile covers how it works, side effects in plain language, and its trial history.
Where Narcolepsy Type 1 treatment stands today
Read our full Narcolepsy Type 1 treatment summary
Medications enhancing central nervous system wakefulness form the foundation of therapy: stimulants including modafinil (first-line), armodafinil, methylphenidate, and amphetamine derivatives manage excessive daytime sleepiness. Sodium oxybate (GHB) addresses both EDS and cataplexy and improves nighttime sleep, and it requires careful dosing and patient education.
Pitolisant, a histamine H3-receptor antagonist, offers an alternative mechanism for both EDS and cataplexy and is gaining clinical adoption. Selective serotonin or norepinephrine reuptake inhibitors (SSRIs/SNRIs) manage cataplexy alone.
In August 2026 the FDA approved oveporexton (Orzeyful), a twice-daily orexin receptor 2 agonist and the first medicine to directly target the loss of orexin signaling behind narcolepsy type 1, for adults.
It can be sold only after the DEA completes controlled substance scheduling, which Takeda expected by November 2026. Behavioral strategies including scheduled naps (10-20 minutes), strict sleep hygiene, avoidance of sedating medications, and comprehensive safety measures optimize quality of life.
Other orexin receptor 2 agonists, including ALKS 2680 (NCT07455383) and ORX750 (NCT06752668), are being tested in clinical trials.
Genetic counseling helps families understand disease mechanism and inheritance patterns. Work with sleep medicine specialists experienced in narcolepsy management.
The Narcolepsy Type 1 page has every treatment and trial →Meanwhile, 20 Narcolepsy Type 1 studies are open or about to open
The FDA's decision does not end research on Narcolepsy Type 1. Of these, 18 test a treatment; the others follow patients over time. The most recently updated:
You'll hear about future FDA decisions and new recruiting trials for Narcolepsy Type 1. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
Has the FDA decided on Orzeyful?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: Takeda press release
What was Orzeyful approved for?
The FDA approved Takeda's NDA for Orzeyful in Narcolepsy type 1.
What to know: Approved August 5, 2026 for adults with narcolepsy type 1 (narcolepsy with cataplexy). The FDA called it the first medicine to work by directly targeting the loss of orexin signaling that causes the disease. It is a tablet taken twice daily. It can be sold only after the DEA completes controlled substance scheduling, and Takeda listed expected availability by November 2026.
How it works: Oral orexin receptor 2 (OX2R) agonist that switches on the receptor normally activated by orexin, the wake-promoting brain chemical lost in narcolepsy type 1.
More: the Orzeyful drug page explains it in plain language.
Is there already an FDA-approved treatment for Narcolepsy Type 1?
Yes. Trial Friend's drug list includes 1 FDA-approved drug for Narcolepsy Type 1.
Approved: Orzeyful (oveporexton).
Check: the Narcolepsy Type 1 page also searches FDA drug labels for approved treatments.
What did the Orzeyful trials show?
Approval rested on 2 Phase 3 trials that lasted 12 weeks: FirstLight (NCT06470828, 168 people, 1mg or 2mg twice daily or placebo) and RadiantLight (NCT06505031, 105 people, 2mg twice daily or placebo). The main goal was the Maintenance of Wakefulness Test (MWT), which measures how long a person can stay awake in a quiet, dark room, up to 40 minutes.
More: the Orzeyful drug page has the full trial history and sources.
What are the side effects of Orzeyful?
Orzeyful has no boxed warning. It must not be taken with strong CYP3A inhibitors such as itraconazole, which raised oveporexton levels about 7-fold.
Most common: Insomnia (60% on 2mg against 1% on placebo), Frequent urination (58% against 5%), Urgent need to urinate (16% against 1%), Extra saliva (7% against 0%).
More: the Orzeyful drug page has the label's warnings in full.
How much will Orzeyful cost?
Trial Friend does not list a price for Orzeyful. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Orzeyful decision?
The FDA approved Orzeyful for Narcolepsy type 1 on August 5, 2026.
Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
Where this outcome comes from
The outcome on this page comes from Takeda press release. This page rechecks against our calendar, which is re-verified daily.